Lung cancer: developments, concepts, and specific aspects of the new WHO classification

Petersen, Iver; Warth, Arne

doi:10.1007/s00432-015-2004-4

Cited by 40 publications

(31 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, 60.0 % (9/15) EGFRmutated ASC patients demonstrated a response to EGFR TKIs, while in SCC and LCLC, the results were 30.8 % (8/26) and 30.0 % (3/10), respectively, which were similar to previous studies (Shukuya et al 2011). Some experts hold the view that some EGFR-mutated SCC and LCLC patients may also have a mixed adenocarcinoma histology and that the sensitivity of EGFR TKIs in those patients may depend on the proportion of EGFR-mutated adenocarcinoma components in the entire tumor (Ohtsuka et al 2007;Hata et al 2013;Petersen and Warth 2015). In this study, most patients were diagnosed based on a small diagnostic biopsy.…”

Section: Discussionsupporting

confidence: 73%

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Zhang

Jin

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Zhang

Jin

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Based on its biological characteristics and clinical manifestations, lung cancer can be classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (3). Small-cell lung tumors undergo metastasis more rapidly than NSCLC to other organs, such as the brain, skeleton, and lymph tissues (4).…”

Section: Introductionmentioning

confidence: 99%

Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Population-based cohort studies have revealed that neuroleptic medications are associated with a reduced cancer risk. Recent studies have demonstrated that selective serotonin reuptake inhibitors (SSRIs) have an antiproliferative or cytotoxic effect on certain cancer types. Known as a superior SSRI, escitalopram oxalate exhibits favorable tolerability with generally mild and temporary adverse events. The present study aimed to examine the effects of escitalopram oxalate on non-small cell lung cancer (NSCLC) cells. The experimental results revealed that escitalopram oxalate significantly inhibited the proliferation and invasion of A549, and H460 cells compared with BEAS-2B cells. Additionally, escitalopram oxalate significantly increased the sub-G 1 population and caspase-3 activity of A549, and H460 cells. Furthermore, escitalopram oxalate significantly induced mitochondria-dependent apoptotic signaling cascades in A549 and H460 cells, which included increases in the protein expression levels of apoptosis regulator Bax, truncated BH3-interacting domain death agonist, cytochrome c, apoptotic protease-activating factor 1, and cleaved caspase-9. These findings suggest that escitalopram oxalate could serve a therapeutic agent for the treatment of NSCLC due to its antiproliferative and apoptotic effects.

show abstract

“…Zu Auswirkungen auf die Tumorklassifikation durch quasi entitätsdefinie-rende Immunmarker am Resektat sei auf eine kürzlich publizierte Übersichtsarbeit verwiesen [13]. Ein bislang in der Routinediagnostik bei NSCLC unzureichend genutzter immunhistochemischer Marker ist der Ki-67-Proliferationsindex.…”

Section: Diagnostisch Und Prognostisch Relevante Immunhistochemische unclassified

“…Zu umfassenderen Übersichten zu diesen Themenkomplexen sei zudem auf bereits kürzlich publizierte Arbeiten verwiesen [3, 13,19,20,35,36].…”

unclassified

Diagnose, Prognose und Prädiktion nicht-kleinzelliger Lungenkarzinome

Warth

2015

Pathologe

View full text Add to dashboard Cite

Tumor diagnostics are based on histomorphology, immunohistochemistry and molecular pathological analysis of mutations, translocations and amplifications which are of diagnostic, prognostic and/or predictive value. In recent decades only histomorphology was used to classify lung cancer as either small (SCLC) or non-small cell lung cancer (NSCLC), although NSCLC was further subdivided in different entities; however, as no specific therapy options were available classification of specific subtypes was not clinically meaningful. This fundamentally changed with the discovery of specific molecular alterations in adenocarcinoma (ADC), e.g. mutations in KRAS, EGFR and BRAF or translocations of the ALK and ROS1 gene loci, which now form the basis of targeted therapies and have led to a significantly improved patient outcome. The diagnostic, prognostic and predictive value of imaging, morphological, immunohistochemical and molecular characteristics as well as their interaction were systematically assessed in a large cohort with available clinical data including patient survival. Specific and sensitive diagnostic markers and marker panels were defined and diagnostic test algorithms for predictive biomarker assessment were optimized. It was demonstrated that the semi-quantitative assessment of ADC growth patterns is a stage-independent predictor of survival and is reproducibly applicable in the routine setting. Specific histomorphological characteristics correlated with computed tomography (CT) imaging features and thus allowed an improved interdisciplinary classification, especially in the preoperative or palliative setting. Moreover, specific molecular characteristics, for example BRAF mutations and the proliferation index (Ki-67) were identified as clinically relevant prognosticators. Comprehensive clinical, morphological, immunohistochemical and molecular assessment of NSCLCs allow an optimized patient stratification. Respective algorithms now form the backbone of the 2015 lung cancer World Health Organization (WHO) classification.

show abstract

Lung cancer: developments, concepts, and specific aspects of the new WHO classification

Cited by 40 publications

References 51 publications

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells

Diagnose, Prognose und Prädiktion nicht-kleinzelliger Lungenkarzinome

Contact Info

Product

Resources

About